Larimar Therapeutics (Nasdaq:LRMR) - Cotización, noticias y análisis

Resumen de acción LRMR

Larimar Therapeutics, Inc, una empresa biotecnológica en fase clínica, se centra en el desarrollo de tratamientos para enfermedades raras utilizando su novedosa plataforma tecnológica de péptidos que penetran en las células.

Acerca de la empresa

LRMR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Se prevé que los beneficios disminuyan una media de 12.3% al año durante los próximos 3 años.

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

+ 1 riesgos adicionales

Competidores de Larimar Therapeutics, Inc.

Shattuck Labs

NasdaqGS:STTK

US$426.3m

CareDx

NasdaqGM:CDNA

US$406.5m

Ocugen

NasdaqCM:OCGN

US$407.8m

Replimune Group

NasdaqGS:REPL

US$438.9m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Larimar Therapeutics
Historical stock prices
Current Share Price	US$7.30
52 Week High	US$13.68
52 Week Low	US$2.18
Beta	0.74
1 Month Change	-12.57%
3 Month Change	68.20%
1 Year Change	48.37%
3 Year Change	-32.09%
5 Year Change	n/a
Change since IPO	-40.65%

Noticias y actualizaciones recientes

Recent updates

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08

Rentabilidad de los accionistas

	LRMR	US Biotechs	Mercado US
7D	6.7%	-5.0%	-3.5%
1Y	48.4%	-1.7%	20.2%

Rentabilidad vs. Industria: LRMR superó al sector US Biotechs , que obtuvo un rendimiento del 4% el año pasado.

Rentabilidad vs. Mercado: LRMR superó al mercado US, que obtuvo un rendimiento del 20.6% el año pasado.

Volatilidad de los precios

Is LRMR's price volatile compared to industry and market?
LRMR volatility
LRMR Average Weekly Movement	16.8%
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: LRMRha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: LRMR(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	42	Carole Ben-Maimon	www.larimartx.com

Larimar Therapeutics, Inc, empresa de biotecnología en fase clínica, se centra en el desarrollo de tratamientos para enfermedades raras utilizando su novedosa plataforma tecnológica de péptidos que penetran en las células. Su principal producto candidato es el CTI-1601, que se encuentra en la fase 2 del ensayo clínico OLE para el tratamiento de la ataxia de Friedreich, una enfermedad genética rara, progresiva y mortal. Larimar Therapeutics, Inc. tiene su sede en Bala Cynwyd, Pensilvania.

Resumen de fundamentos de Larimar Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Larimar Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de LRMR
Capitalización bursátil	US$461.91m
Beneficios(TTM)	-US$36.95m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-12.6x

Ratio precio-beneficio (PE)

¿Está LRMR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de LRMR
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$36.95m
Beneficios	-US$36.95m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.58
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado LRMR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción LRMR

Recompensas

Análisis de riesgos

Competidores de Larimar Therapeutics, Inc.

NasdaqGS:STTK

US$426.3m

NasdaqGM:CDNA

US$406.5m

NasdaqCM:OCGN

US$407.8m

NasdaqGS:REPL

US$438.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Price target increased by 41% to US$16.24

Recent updates

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Price target increased by 41% to US$16.24

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Price target decreased to US$10.59

High number of new and inexperienced directors

Laramar Therapeutics issued patent for lead pipeline candidate

CEO, President & Director recently bought US$100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics prices ~$70M stock offering

Price target increased to US$6.23

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

Larimar Therapeutics GAAP EPS of -$0.47

Price target increased to US$5.88

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Price target decreased to US$13.50

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Independent Director recently bought US$496k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

New 90-day low: US$17.75

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

New 90-day high: US$22.50

Larimar Therapeutics reports Q3 results

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high: US$18.91

New 90-day high - US$16.00

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Larimar Therapeutics, Inc.

0.0x

-12.6x

Beneficios e Ingresos